{"protocolSection":{"identificationModule":{"nctId":"NCT05401149","orgStudyIdInfo":{"id":"0135-0349"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients","officialTitle":"Effectiveness and Safety of IV Rt-PA Treatment in Chinese AIS Patients Aged Above 80 Years: a Real-world Study"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-07-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-14","type":"ACTUAL"},"completionDateStruct":{"date":"2022-12-14","type":"ACTUAL"},"studyFirstSubmitDate":"2022-05-25","studyFirstSubmitQcDate":"2022-06-01","studyFirstPostDateStruct":{"date":"2022-06-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-23","lastUpdatePostDateStruct":{"date":"2022-12-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom onset in a real-world clinical setting."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":1301,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IV rt-PA cohort","description":"Intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) cohort: AIS patients aged \\> 80 years who received IV rt-PA within 4.5 hours of symptom onset","interventionNames":["Drug: rt-PA"]},{"label":"Non-reperfusion cohort","description":"Non-reperfusion cohort: AIS patients aged \\> 80 years who arrived or admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatments"}],"interventions":[{"type":"DRUG","name":"rt-PA","description":"Recombinant Tissue Plasminogen Activator","armGroupLabels":["IV rt-PA cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"modified Rankin Scale (mRS) score of 0-1 at 1 year","description":"The modified Rankin Scale (mRS) is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, from 'perfect health without symptoms' to 'death'. 0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","timeFrame":"up to 1 year"}],"secondaryOutcomes":[{"measure":"Intracranial haemorrhage (ICH) during hospitalisation","timeFrame":"up to 3 months"},{"measure":"All-cause mortality during hospitalisation","timeFrame":"up to 3 months"},{"measure":"mRS score of 0-2 at 1 year","timeFrame":"up to 1 year"},{"measure":"Distribution of mRS score at 1 year","timeFrame":"up to 1 year"},{"measure":"All-cause mortality at 1 year","timeFrame":"up to 1 year"},{"measure":"Baseline characteristics: Age","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Gender","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Body weight","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Medical insurance status","description":"urban employee basic medical insurance, urban resident basic medical insurance, new rural cooperative medical insurance, other insurance, no insurance","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Smoking status","description":"current smoker, former smoker, never smoker","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Stroke severity","description":"Stroke severity is measured via the National Institutes of Health Stroke Scale (NIHSS). The NIHSS score ranges from 0 to 42. Higher scores indicate more severe neurological impairment.","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Time from symptom onset to hospital admission","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Time from symptom onset to treatment","description":"for patients in the IV rt-PA cohort","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Time from hospital admission to treatment","description":"for patients in the IV rt-PA cohort","timeFrame":"at baseline"},{"measure":"Baseline characteristics: rt-PA dosage","description":"for patients in the IV rt-PA cohort","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Number of subjects with Comorbidities","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Number of subjects with Co-medication","timeFrame":"at baseline"},{"measure":"Baseline characteristics: Hospital level (grade 2 or 3)","timeFrame":"at baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Patients registered in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from Jan 2017 to Mar 2020\n* \\> 80 years of age\n* Diagnosed with AIS at admission\n* Arrived or admitted to the hospital within 4.5 hours of symptom onset\n* If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset\n\nExclusion criteria:\n\n* Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)\n* Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \\[NIHSS\\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)\n* Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)\n* Received endovascular treatment\n* Received IV rt-PA after 4.5 hours of symptom onset","healthyVolunteers":false,"sex":"ALL","minimumAge":"80 Years","stdAges":["OLDER_ADULT"],"studyPopulation":"In this study, AIS patient data from 80 stroke centres in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from January 2017 to March 2020 will be used.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Boehringer Ingelheim (China) Investment Co., ltd.","city":"Shanghai","zip":"200040","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://www.mystudywindow.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).\n\nFor more details refer to: https://www.mystudywindow.com/msw/datatransparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2023-12-12","submissionInfos":[{"releaseDate":"2023-12-12"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}